Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Novartis Venture Fund

Novartis Venture Fund

A corporate venture capital firm in Switzerland that focuses on companies that develop novel therapeutics and platforms

Novartis Venture Fund is a corporate venture capital firm in Switzerland that focuses on companies that develop novel therapeutics and platforms. Founded 1996 in Basel-Stadt, Switzerland by Argeris Karabelas, it invests in early stage ventures, late stage venture, post-IPO, secondary markets, seed, series A, series B, series C, and post-IPO equity. Its portfolio companies include TScan Therapeutics, GenSight Biologics, FORMA Therapeutics, Arctos Medical, and Enterprise Therapeutics. As of March 2020, Novartis Venture Fund has made 200 investments. Their most recent investment was on January 10, 2020, when TScan Therapeutics raised $35M. Novartis Venture Fund has had 51 exits, the most notable of which include PTC Therapeutics, Bicycle Therapeutics, and Akebia Therapeutics. The company has raised three funds, their latest being Novartis Option Fund (NOF). This fund was announced on January 1, 2009 and raised a total of $200M.

Timeline

2015
Founded

Invested in

Patents

Funding Rounds Participated In

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

News

Title
Author
Date
Publisher
Description
FinSMEs
August 19, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
May 17, 2021
BioSpace
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures - read this article along with other careers information, tips and advice on BioSpace

References

Golden logo
By using this site, you agree to our Terms & Conditions.